Vericel (VCEL) Current Leases (2019 - 2026)
Vericel (VCEL) posted Current Leases of $14.2 million for Q2 2026, up 0.68% sequentially from $14.1 million in Q1 2026, and up 2.94% YoY from $13.8 million in Q2 2025.
Analysis
Vericel (VCEL) Current Leases (2019 - 2026) Analysis & Trends
Vericel has reported Current Leases for 8 years, with the latest figure at $14.2 million in Q2 2026.
- Quarterly Current Leases rose 2.94% year-over-year to $14.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $14.2 million (up 2.94% YoY) and the FY2025 annual result came in at $14.0 million, up 50.9% from the prior year.
- Current Leases rose to $14.2 million in Q2 2026 per VCEL's latest filing, from $14.1 million in the prior quarter.
- Over five years, Current Leases peaked at $14.2 million in Q2 2026 and troughed at $3.2 million in Q2 2022.
- A 5-year average of $8.3 million and a median of $6.7 million in 2023 frame the typical range for Current Leases.
- The sharpest annual moves came in 2022 and 2025: Current Leases tumbled 32.16% in 2022, then soared 137.49% in 2025.
- Over 5 years, Current Leases stood at $4.3 million in 2022, then jumped by 43.82% to $6.2 million in 2023, then jumped by 49.62% to $9.3 million in 2024, then soared by 50.9% to $14.0 million in 2025, then advanced by 1.35% to $14.2 million in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $14.2 million, $14.1 million, and $14.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 14.16 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 14.16 Mn |
| Mar 31, 2026 | 14.06 Mn |
| Dec 31, 2025 | 13.97 Mn |
| Sep 30, 2025 | 13.85 Mn |
| Jun 30, 2025 | 13.75 Mn |
| Mar 31, 2025 | 11.16 Mn |
| Dec 31, 2024 | 9.26 Mn |
| Sep 30, 2024 | 6.12 Mn |
| Jun 30, 2024 | 5.79 Mn |
| Mar 31, 2024 | 6.01 Mn |
| Dec 31, 2023 | 6.19 Mn |
| Sep 30, 2023 | 7.27 Mn |
| Jun 30, 2023 | 7.22 Mn |
| Mar 31, 2023 | 4.50 Mn |
| Dec 31, 2022 | 4.30 Mn |
| Sep 30, 2022 | 4.90 Mn |
| Jun 30, 2022 | 3.16 Mn |
| Mar 31, 2022 | 3.19 Mn |
| Dec 31, 2021 | 2.95 Mn |
| Sep 30, 2021 | 2.32 Mn |